Thymosin Alpha-1 — immune resilience peptide.

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide that the thymus gland produces naturally. It plays a role in T-cell maturation and overall immune system balance. Synthetic Tα1 has been used clinically outside the U.S. for decades — particularly for chronic hepatitis B/C and immune support in cancer patients.

In the U.S., Tα1 is available through 503A compounding for off-label use under physician supervision. It is not a stimulant of the immune system and not an immunosuppressant — it's a modulator, helping the immune system function appropriately.

Tα1 activates Toll-like receptors (TLR2, TLR9) on dendritic cells, modulates T-cell maturation and Th1/Th2 balance, and influences cytokine production. The net effect is a more appropriate immune response — improved function when the immune system is suppressed, more balanced response when it's dysregulated.

Thymosin Alpha-1 makes clinical sense for:

• Patients dealing with frequent illness or slow recovery from infections
• Post-viral recovery (post-COVID, post-EBV reactivation)
• Chronic immune dysregulation patterns
• Stress-driven immune suppression

Typical clinical protocols: 1.6mg subcutaneous injection, twice weekly. Cycles vary by indication — 4–12 week courses are common. Some patients use ongoing low-dose maintenance.

Patients dealing with post-viral fatigue typically report gradual improvement over 4–8 weeks. Frequency-of-illness reduction usually shows up over a 3–6 month period.

Vektor prescribes Thymosin Alpha-1 through our 503A pharmacy partner — standard format is 5mg/mL in a 5mL vial. One vial covers approximately one month of standard dosing.